scispace - formally typeset
Search or ask a question

Showing papers by "Barry J. Materson published in 2002"


Journal ArticleDOI
TL;DR: Even mild elevation of blood pressure may be sufficient to activate the expression of adhesion molecules in humans, and Mechanisms other than the endothelial expression ofAdhesion molecules may be important in mediating the accelerated target organ injury produced by SHT in humans.
Abstract: Objectives The molecular mechanisms whereby severe, uncontrolled hypertension (SHT) is translated into acute vascular target organ dysfunction have not been completely defined. We sought to determine whether SHT is associated with pressure-dependent endothelial activation as assessed by soluble vasc

66 citations


Journal ArticleDOI
TL;DR: It is found that the literature does not support a definitive conclusion either in favor of or against an overall drug-specific protective effect, but by grouping like trials, it is possible to support an additional protective effect by angiotensin-converting enzyme inhibitors and angiotENSin II receptor blockers on reducing the rate of decline in renal function and in reducing proteinuria.
Abstract: Reduction of elevated blood pressure clearly protects against target organ damage, but the different targets do not necessarily benefit to the same degree. There is considerable debate over whether or not there is a drug-specific benefit above and beyond that conferred by blood pressure reduction alone. We performed a Medline search to identify recent randomized clinical trials including 300 or more patients who were followed for at least 2 years. We critically reviewed these papers to find like trials for comparisons. There was too much dissimilarity to perform a meaningful meta-analysis. We found that the literature does not support a definitive conclusion either in favor of or against an overall drug-specific protective effect. However, by grouping like trials, it is possible to support an additional protective effect by angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on reducing the rate of decline in renal function and in reducing proteinuria.

6 citations